Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simlukafusp alfa + atezolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Simlukafusp alfa + atezolizumab is a combination investigational immunotherapy regimen evaluated mainly in advanced or metastatic solid tumors. **Simlukafusp alfa (FAP-IL2v, RO6874281)** is an immunocytokine that targets fibroblast activation protein alpha (FAP) on tumor stroma, fused to an interleukin-2 (IL2) variant designed to preferentially signal through IL2 receptor beta-gamma (IL2Rβγ) rather than alpha, favoring activation of cytotoxic immune cells over regulatory T cells. **Atezolizumab** is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), blocking immune evasion by cancer cells. The combination aims to synergize immune activation and checkpoint inhibition. Clinical studies have evaluated safety, pharmacokinetics, and antitumor activity of the combination in various solid tumors, including head and neck, esophageal, and cervical squamous cell carcinomas. Development of simlukafusp alfa was discontinued for portfolio prioritization, not efficacy or safety concerns[1][2][3][5].
- Other names
- FAP-IL2v + atezolizumab
02
Targets
IL2RB (IL-2 receptor beta chain)FAP (Fibroblast activation protein alpha)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on simlukafusp alfa + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simlukafusp alfa + atezolizumab.